BiotechTube

SYNB1934v1 + Placebo

Phase 3Terminated
0 watching 0 views this week📈 Rising
69
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonuria

Conditions

Phenylketonuria

Trial Timeline

Jul 5, 2023 → Mar 15, 2024

NCT ID
NCT05764239

About SYNB1934v1 + Placebo

SYNB1934v1 + Placebo is a phase 3 stage product being developed by Synlogic for Phenylketonuria. The current trial status is terminated. This product is registered under clinical trial identifier NCT05764239. Target conditions include Phenylketonuria.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05764239Phase 3Terminated

Competing Products

20 competing products in Phenylketonuria

See all competitors
ProductCompanyStageHype Score
SYNB1618 + PlaceboSynlogicPhase 1/2
33
SYNB1618 + SYNB1934SynlogicPhase 2
44
Kuvan®MerckPhase 3
77
Kuvan®MerckApproved
85
SAR444836SanofiPhase 1/2
40
KuvanBioMarin PharmaceuticalPre-clinical
20
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
49
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
49
Sapropterin (Kuvan)BioMarin PharmaceuticalPre-clinical
20
BMN 165 (rAvPAL-PEG)BioMarin PharmaceuticalPhase 2
49
BMN 307BioMarin PharmaceuticalPhase 1/2
38
SapropterinBioMarin PharmaceuticalPre-clinical
20
Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
74
BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
74
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
74
saproterin dihydrochlorideBioMarin PharmaceuticalApproved
82
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placeboBioMarin PharmaceuticalPhase 1
30
PegvaliaseBioMarin PharmaceuticalPre-clinical
20
PegvaliaseBioMarin PharmaceuticalPre-clinical
20
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 2
49

Other Products from Synlogic

SYNB1618 + SYNB1934Phase 2
44
SYNB1618 + PlaceboPhase 1/2
33
SYNB1020Phase 1/2
33
SYNB1891 + AtezolizumabPhase 1
25
Placebo + SYNB1020Phase 1
25